Flag of the European Union EU Clinical Trials Register Help

Clinical trials for placebo treatment

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44394   clinical trials with a EudraCT protocol, of which   7406   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    10,665 result(s) found for: placebo treatment. Displaying page 322 of 534.
    «« First « Previous 318  319  320  321  322  323  324  325  326  Next» Last»»
    EudraCT Number: 2018-002610-12 Sponsor Protocol Number: CAIN457ADE11C Start Date*: 2018-12-06
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A randomized, parallel-group, double-blind, placebo-controlled, multicenter phase 2 trial to investigate the safety and efficacy of secukinumab (AIN457) in patients with giant cell arteritis (TitAIN)
    Medical condition: Giant Cell Arteritis
    Disease: Version SOC Term Classification Code Term Level
    23.1 10047065 - Vascular disorders 10018250 Giant cell arteritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2022-003633-19 Sponsor Protocol Number: SYN321-01 Start Date*: 2023-04-05
    Sponsor Name:Synartro AB
    Full Title: A prospective, double-blinded, randomized, placebo-controlled phase 1/2a study to assess safety, tolerability, systemic exposure, and preliminary efficacy of single intraarticular injections of 3 d...
    Medical condition: Knee osteoarthritis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004859 10023476 Knee osteoarthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-001682-12 Sponsor Protocol Number: MYOFLAME-19 Start Date*: 2023-06-16
    Sponsor Name:Goethe University Frankfurt
    Full Title: Randomised placebo controlled clinical trial of efficacy of MYOcardial protection with postacute inFLAMmatory cardiac involvEment due to COVID-19 (MYOFLAME-19)
    Medical condition: Inflammatory cardiovascular involvement due to COVID-19, defined by Cardiovascular magnetic resonance imaging
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    20.0 10007541 - Cardiac disorders 10007650 Cardiovascular disorder NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004155-37 Sponsor Protocol Number: A01-115-02-EU Start Date*: 2020-07-30
    Sponsor Name:Aptabio Therapeutics, Inc
    Full Title: A randomized, Placebo-controlled, Double-blinded, Multi-centre, Phase 2 Study to Assess Safety, Tolerability and Renal Effects of APX-115 in Subjects with Type 2 Diabetes and Nephropathy
    Medical condition: diabetic nephropathy
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10061835 Diabetic nephropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-006082-11 Sponsor Protocol Number: ADG20-TRMT-001 Start Date*: 2021-06-02
    Sponsor Name:Adagio Therapeutics Inc.
    Full Title: A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of ADG20 in the Treatment of Ambulatory Participants with Mild or Moderate COVID-19 (STAMP)
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10084382 Coronavirus disease 2019 LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Prematurely Ended) DE (Prematurely Ended) HU (Completed) BG (Prematurely Ended) PL (Prematurely Ended) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2009-017772-25 Sponsor Protocol Number: CQVA149A2303 Start Date*: 2010-10-11
    Sponsor Name:Novartis Pharma AG
    Full Title: A 26-week treatment multi-center, randomized, doubleblind, parallel-group, placebo and active controlled (open label) study to assess the efficacy, safety and tolerability of QVA149 (110/50 μg q.d....
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) HU (Completed) ES (Completed) FR (Completed) DE (Completed) GB (Completed) BG (Completed) NL (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2007-000175-42 Sponsor Protocol Number: BO20904 Start Date*: 2007-12-21
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A double-blind, randomised, multicenter, phase III study of bevacizumab in combination with capecitabine and cisplatin versus placebo in combination with capecitabine and cisplatin, as first-line t...
    Medical condition: Adult and elderly patients with histologically confirmed, inoperable, locally advanced or metastatic adenocarcinoma of the stomach or gastro-oesophageal junction, who have received no prior treatme...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063916 Metastatic gastric cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) GB (Completed) DE (Completed) IT (Completed)
    Trial results: Removed from public view
    EudraCT Number: 2014-004094-17 Sponsor Protocol Number: 40-41200-98-9269 Start Date*: 2015-11-03
    Sponsor Name:Universiteit Utrecht
    Full Title: Cannabidiol enhancement of exposure therapy in treatment refractory patients with phobias.
    Medical condition: Phobic anxiety disorders: either generalized social phobia or panic disorder with agoraphobia.
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004873 10068299 Fear symptoms and phobic disorders (incl social phobia) HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: View results
    EudraCT Number: 2017-004916-21 Sponsor Protocol Number: EROS Start Date*: 2019-07-02
    Sponsor Name:Karolinska Institute
    Full Title: Early intervention and recovery of sexual function in men and women after treatment of rectal cancer–a randomized controlled study with tadalafil compared to standard care
    Medical condition: sexual/ erectile function in women and men after treatment for rectal cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038604 - Reproductive system and breast disorders 10013356 Sexual function and fertility disorders HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-003927-45 Sponsor Protocol Number: SENS-111-201 Start Date*: 2017-05-04
    Sponsor Name:Sensorion SA
    Full Title: A multicentre, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of 2 dose regimens of orally administered SENS-111 (100mg and 200mg) given during 4 days in patie...
    Medical condition: Acute Unilateral Vestibulopathy
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10047393 Vestibular neuronitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) HU (Completed) ES (Prematurely Ended) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-015621-36 Sponsor Protocol Number: EMR200066-004 Start Date*: 2010-02-15
    Sponsor Name:Merck Serono S.A., Geneva
    Full Title: Estudio aleatorizado, multicéntrico, doble ciego, comparativo, exploratorio y controlado con placebo en fase II con FOLFIRI en combinación con MSC1936369B o placebo, con una "safety run-in part", c...
    Medical condition: Cancer Colorrectal metastásico (segunda línea)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10052358 Colorectal cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-002416-41 Sponsor Protocol Number: 201000 Start Date*: 2017-02-17
    Sponsor Name:GlaxoSmithKline, S.A.
    Full Title: A randomized, double-blind, multi-dose, placebo-controlled study to evaluate the efficacy, safety and tolerability of GSK2330672 administration for the treatment of pruritus in patients with primar...
    Medical condition: Primary biliary cholangitis (PBC)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10019805 - Hepatobiliary disorders 10008604 Cholangitis PT
    19.0 10040785 - Skin and subcutaneous tissue disorders 10037087 Pruritus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-005225-54 Sponsor Protocol Number: 248.615 Start Date*: 2006-07-10
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A phase IV randomised, double-blind, placebo-controlled, dose titration trial with pramipexole (Sifrol®, Mirapexin®) 0.125-0.75 mg/day per os for 12 weeks to investigate the effects on RLS symptoms...
    Medical condition: Restless Legs Syndrome
    Disease: Version SOC Term Classification Code Term Level
    8.1 10058920 pref
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IE (Completed) FI (Completed) DK (Completed) ES (Completed) IT (Completed) SE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-003697-10 Sponsor Protocol Number: 109MS302 Start Date*: 2007-04-13
    Sponsor Name:Biogen Idec Ltd.
    Full Title: A Randomized, Multicenter, Placebo-Controlled and Active Reference (Glatiramer Acetate) Comparison Study to Evaluate the Efficacy and Safety of BG00012 in Subjects With Relapsing-Remitting Multiple...
    Medical condition: Relapsing-Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10063399 Relapsing-remitting multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) BE (Completed) ES (Completed) IE (Completed) GR (Completed) EE (Completed) LV (Completed) BG (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-004274-41 Sponsor Protocol Number: 54861911ALZ2004 Start Date*: 2015-05-29
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Randomized, Two-Period, Double-Blind Placebo-Controlled and Open-Label, Multicenter Extension Study to Determine the Long-Term Safety and Tolerability of JNJ-54861911 in Subjects in the Early Alz...
    Medical condition: Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) SE (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) FR (Completed) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-014940-12 Sponsor Protocol Number: CL2-44121-006 Start Date*: 2010-03-11
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Evaluation of the anti-arrhythmic effects of 3 oral dosages of S 44121 versus placebo in patients with chronic heart failure and left ventricular systolic dysfunction at risk for ventricular arrhyt...
    Medical condition: Chronic Heart Failure and left ventricular systolic dysfunction at risk for ventricular arrhythmia
    Disease: Version SOC Term Classification Code Term Level
    12.1 10007558 Cardiac failure chronic LLT
    12.1 10049694 Left ventricular dysfunction LLT
    12.1 10047281 Ventricular arrhythmia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) HU (Completed) SK (Completed) ES (Completed) PT (Completed) GB (Completed) CZ (Completed) DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2013-000001-23 Sponsor Protocol Number: 14861B Start Date*: 2014-02-27
    Sponsor Name:H. Lundbeck A/S
    Full Title: An open-label extension study to evaluate the long-term safety and tolerability of Lu AE58054 as adjunctive treatment to donepezil in patients with mild-moderate Alzheimer's disease
    Medical condition: Alzheimer´s disease
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) EE (Completed) IT (Completed) BE (Completed) LT (Completed) ES (Completed) DK (Completed) BG (Completed) PT (Completed) GB (Completed) HU (Completed) FI (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2021-000227-13 Sponsor Protocol Number: PHA022121-C301 Start Date*: 2022-02-02
    Sponsor Name:Pharvaris Netherlands BV
    Full Title: A Phase II, Double-blind, Placebo-controlled, Randomized, Dose-ranging, Parallel Group Study to Evaluate the Safety and Efficacy of PHA-022121 Administered Orally for Prophylaxis Against Angioedema...
    Medical condition: Hereditary angioedema due to C1-Inhibitor Deficiency (Type I or Type II)
    Disease: Version SOC Term Classification Code Term Level
    23.1 10010331 - Congenital, familial and genetic disorders 10019860 Hereditary angioedema PT
    26.0 10010331 - Congenital, familial and genetic disorders 10080960 Hereditary angioedema type II LLT
    21.0 10010331 - Congenital, familial and genetic disorders 10080957 Hereditary angioedema C1 inhibitor deficiency LLT
    21.0 10010331 - Congenital, familial and genetic disorders 10080956 Hereditary angioedema type I LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned) BG (Trial now transitioned) IT (Trial now transitioned) AT (Trial now transitioned) IE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-000593-38 Sponsor Protocol Number: MR308-3502 Start Date*: 2016-12-05
    Sponsor Name:Mundipharma Research GmbH & Co. KG
    Full Title: A Randomized, Double-Blind, Multicenter, Placebo- and active Comparator-Controlled Study to evaluate Efficacy and Safety of MR308 in the Treatment of Acute Pain After Abdominal Hysterectomy Surgery...
    Medical condition: Acute pain after open total or subtotal abdominal hysterectomy
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004867 10066714 Acute pain LLT
    Population Age: Adults Gender: Female
    Trial protocol: ES (Completed) SK (Completed) LV (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2017-003293-14 Sponsor Protocol Number: RVT-901-3003 Start Date*: 2018-07-06
    Sponsor Name:Urovant Sciences GmbH
    Full Title: An International Phase 3, Randomized, Double-Blind, Placebo- and Active (Tolterodine)-Controlled Multicenter Study to Evaluate the Safety and Efficacy of Vibegron in Patients with Symptoms of Overa...
    Medical condition: Adult men and women with either: •OAB Wet • OAB Dry
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004857 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) HU (Completed) EE (Completed) BG (Prematurely Ended) LT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 318  319  320  321  322  323  324  325  326  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 28 18:54:47 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA